Skip to main content

Advertisement

SpringerLink
Log in

Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Peritoneal fibrosis is almost uniform feature encountered in peritoneal dialysis patients. The transition of epithelial cells to mesenchymal phenotype, neovascularization, and consequently development of peritoneal fibrosis occur due to the involvement of peritoneal membrane by various insults such as uremia itself, peritonitis attacks, and exposure to bio-incompatible peritoneal dialysis fluids. Bevacizumab is a monoclonal antihuman antibody developed against vascular endothelial growth factor and can reduce fibrosis by preventing neovascularization. There has been no study so far that demonstrates the effect of bevacizumab on peritoneal fibrosis in a rat model.

Methods

A total of 41 female Wistar albino rats were divided into six groups. The control group (C) received 0.9 % isotonic saline (2 ml/day) intraperitoneally (i.p) for 21 days. Chlorhexidine group (CH) received 15 % ethyl alcohol and 0.1 % chlorhexidine gluconate (CG) in saline (2 ml/day) i.p for 21 days. The resting group (R) received CG 2 ml/day i.p for 21 days. The bevacizumab-1 group (B1) received CG 2 ml/day i.p for 21 days and bevacizumab 2.5 mg/kg i.p as a single dose on day 21. The bevacizumab-2 group (B2) received CG 2 ml/day for 21 days and bevacizumab 2.5 mg/kg i.p on day 0 and day 21. The bevacizumab-3 group (B3) received bevacizumab 2.5 mg/kg i.p on day 0 and day 21. Peritoneal samples were taken from the left anterior abdominal wall. The thickness, vascularization, and fibrosis scores in the peritoneal samples were assessed using a light microscope.

Results

On histopathological evaluations, peritoneum thicknesses, vascularization scores, and fibrosis significantly decreased in bevacizumab groups B1 and B2.

Conclusion

Histopathologically, bevacizumab was proven to attenuate fibrotic process in experimental peritoneal sclerosis model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lukowsky LR, Mehrotra R, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K (2013) Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin J Am Soc Nephrol 8(4):619–628

    Article  PubMed Central  PubMed  Google Scholar 

  2. Kawaguchi Y, Saito A, Kawanishi H et al (2005) Recommendations on the management of encapsulating peritoneal sclerosis in japan 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 25(4):S83–S95

    PubMed  Google Scholar 

  3. Davies SJ (2014) Peritoneal solute transport and inflammation. Am J Kidney Dis 64(6):978–986

    Article  CAS  PubMed  Google Scholar 

  4. Morinaga H, Sugiyama H, Inoue T, Takiue K, Kikumoto Y, Kitagawa M et al (2012) Effluent free radicals are associated with residual renal function and predict technique failure in peritoneal dialysis patients. Perit Dial Int 32(4):453–461

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, Lang T et al (2013) Encapsulating peritoneal sclerosis: a rare, serious but potentially curable complication of peritoneal dialysis-experience of a referral centre in Germany. Nephrol Dial Transplant 28(4):1021–1030

    Article  PubMed  Google Scholar 

  6. Krediet RT, Lindholm B, Rippe B (2000) Pathophysiology of peritoneal membrane failure. Perit Dial Int 20(4):S22–S42

    PubMed  Google Scholar 

  7. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K (1996) Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of sclerosing encapsulating peritonitis group. Am J Kidney Dis 28:420–427

    Article  CAS  PubMed  Google Scholar 

  8. Paolo N, Garosi G (1999) Peritoneal sclerosis. J Nephrol 12:347–361

    PubMed  Google Scholar 

  9. Brulez HF, Verbrugh HA (1995) First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 15(S7):S24–S33

    CAS  PubMed  Google Scholar 

  10. Yaῆez-Mo M, Lara-pezzi E, Selgas R et al (2003) Peritoneal dialysis and epithelial to-mesenchymal transition of mesothelial cells. N Eng J Med 348:403–413

    Article  Google Scholar 

  11. Seeger H, Braun N, Latus J, Alscher MD, Fritz P, Edenhofer I et al (2014) Platelet-derived growth factor receptor-β expression in human peritoneum. Nephron Clin Pract 128:178–184

    Article  CAS  PubMed  Google Scholar 

  12. Braun N, Reimold F, Biegger D, Fritz P, Kimmel M, Ulmer C et al (2009) Fibrogenic growth factors in encapsulating peritoneal sclerosis. Nephron Clin Pract 113(2):88–95

    Article  Google Scholar 

  13. Krediet RT, Zweers MM, van der Wal AC, Struijk DG (2000) Neoangiogenesis in the peritoneal membrane. Perit Dial Int 20(2):S19–S25

    PubMed  Google Scholar 

  14. Williams JD, Craig KJ, Topley N et al (2002) Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479

    PubMed  Google Scholar 

  15. Pecoits-Filho R, Araujo MR, Lindholm B et al (2002) Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 17:1480–1486

    Article  CAS  PubMed  Google Scholar 

  16. Goodlad C, Brown AE (2011) Encapsulating peritoneal sclerosis: what have we learned? Semin Nephrol 31:183–198

    Article  PubMed  Google Scholar 

  17. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y (2004) Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 65(5):1927–1936

    Article  CAS  PubMed  Google Scholar 

  18. Lafrannce JP, Lẽtourneau I, Ouimet D et al (2008) Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 51:e7–e10

    Article  Google Scholar 

  19. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S (2005) Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 25(4):S39–S47

    PubMed  Google Scholar 

  20. Del Peso G, Bajo MA, Gil F, Aguilera A et al (2003) Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 19:32–35

    PubMed  Google Scholar 

  21. Sarioglu S, Sis B, Celik A et al (2006) Quantitative digital histochemistry with methenamine silver staining in renal allograft biopsies excluding pure chronic allograft nephropathy cases. Transplant Proc 38:490–491

    Article  CAS  PubMed  Google Scholar 

  22. Gotloib L, Wajsbrot V, Shostak A (1995) Morphology of the peritoneum: effect of peritoneal dialysis. Perit Dial Int 15:9–11

    Google Scholar 

  23. Mandl-Weber S, Cohen CD, Haslinger B, Kretzier M, Sitter T (2002) Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 61:570–578

    Article  CAS  PubMed  Google Scholar 

  24. Stavenuiter AWD, Schilte MN, Ter Wee PM, Beelen RHJ (2011) Angiogenesis in peritoneal dialysis. Kidney Blood Press Res 34:245–252

    Article  CAS  PubMed  Google Scholar 

  25. Kawanishi H, Kawaguchi Y, Fukui H et al (2004) Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 44:729–737

    Article  PubMed  Google Scholar 

  26. Di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR (2010) Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol 248(6):785–791

    Article  CAS  Google Scholar 

  27. Oneill EC, Qin Q, Van Bergen NJ et al (2010) Antifibrotic activity of bevacizumab on human Tenon’s fibroblasts in vitro. Invest Ophthalmol Vis Sci 51(S1):6524–6532

    Article  Google Scholar 

  28. Huang Y, Feng H, Kan T et al (2013) Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. PLoS ONE 8(8):e73492

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Ignjatovic D, Aasland K, Pettersen M et al (2010) Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 200(2):270–275

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir, Turkey

    Sibel Ada, Sibel Ersan, Aykut Sifil, Mehmet Sert & Taner Camsari

  2. Department of Pathology, Dokuz Eylul University Hospital, Izmir, Turkey

    Mehtat Unlu & Sulen Sarioglu

  3. Department of Laboratory Animals Science, Dokuz Eylul University Hospital, Izmir, Turkey

    Efsun Kolatan & Osman Yilmaz

Authors
  1. Sibel Ada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sibel Ersan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aykut Sifil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehtat Unlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Efsun Kolatan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mehmet Sert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sulen Sarioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Osman Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Taner Camsari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sibel Ersan.

Ethics declarations

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ada, S., Ersan, S., Sifil, A. et al. Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis. Int Urol Nephrol 47, 2047–2051 (2015). https://doi.org/10.1007/s11255-015-1116-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-1116-8

Keywords

Search

Navigation